Avicanna Inc. reports Q3 2025 results, showcasing revenue of $6.40 million and $18.88 million for the three- and nine-month periods ended September 30, 2025. Despite short-term margin pressures, gross profit was $3.15 million and $9.88 million, with gross margins at 49% and 52%, respectively. Adjusted EBITDA showed a loss of $0.79 million for the quarter and a slight improvement for the nine-month period. Avicanna also saw commercial advancements in Canada, launched a CBD wellness brand in the US, and completed the first export of CBD flower to Switzerland. – Source: Avicanna Inc.

Avicanna Inc. is a biopharmaceutical company focused on plant-derived cannabinoid-based products. With revenue growth in Canada and international markets, Avicanna continues to develop new IP and global collaborations. The company’s Q3 2025 results reflect their commitment to building a sustainable business model. Avicanna also announced the issuance of a patent covering topical cannabinoid compositions for clear skin by the USPTO. Additionally, Avicanna’s subsidiary completed the export of CBD flower to Switzerland and launched a CBD wellness brand in the US. Stay connected with Avicanna for updates on their innovative products and developments.

Read more at GlobeNewswire: Avicanna Reports Q3 2025